<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647267</url>
  </required_header>
  <id_info>
    <org_study_id>DRCR.net Protocol AG</org_study_id>
    <secondary_id>U10EY014231</secondary_id>
    <secondary_id>U10EY023207</secondary_id>
    <nct_id>NCT03647267</nct_id>
  </id_info>
  <brief_title>Effects of Pneumatic Vitreolysis on Vitreomacular Traction</brief_title>
  <acronym>AG</acronym>
  <official_title>Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eyes with idiopathic symptomatic vitreomacular traction (VMT) without a macular hole will be&#xD;
      randomly assigned to 0.3-mL intraocular gas (C3F8) injection or sham injection to determine&#xD;
      if pneumatic vitreolysis (PVL) is effective in releasing VMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational Device: 0.3-mL intraocular gas (C3F8) injection&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      Primary&#xD;
&#xD;
        1. To compare the proportion of eyes with central VMT release on OCT after pneumatic&#xD;
           vitreolysis with gas injection versus observation (sham injection) in eyes with VMT&#xD;
           without an associated macular hole.&#xD;
&#xD;
           Secondary&#xD;
&#xD;
        2. To evaluate visual function outcomes at 24 weeks after gas injection is performed&#xD;
           compared with sham injection.&#xD;
&#xD;
      Study Design: Multi-center, randomized clinical trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Actual">August 6, 2020</completion_date>
  <primary_completion_date type="Actual">August 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Visual acuity and optical coherence tomography technicians will be masked to treatment group at all visits. The goal is for study participants to remain masked to their treatment group assignment, although it is likely that the gas bubble will be visible to participants in the pneumatic vitreolysis group. Investigators and study coordinators are not masked to treatment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy</measure>
    <time_frame>at 24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Rescue Treatment Before the 24-week Visit</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Rescue Vitrectomy Completed Before the 24-week Visit or Planned at the 24 Week Visit</measure>
    <time_frame>through 24 Weeks</time_frame>
    <description>scheduled rescue vitrectomy must be completed within the subsequent 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Central Vitreomacular Traction Status</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Vitreomacular Traction</condition>
  <arm_group>
    <arm_group_label>Pneumatic Vitreolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the observation group will receive a sham injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pneumatic Vitreolysis (C3F8 injection)</intervention_name>
    <description>Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
    <arm_group_label>Pneumatic Vitreolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>No intervention; sham injection only</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least one eye meets the study eye criteria listed below.&#xD;
&#xD;
          2. Able and willing to provide informed consent.&#xD;
&#xD;
          3. Able and willing to avoid high altitude travel, including airline travel, until gas&#xD;
             resolution (approximately 6 to 8 weeks).&#xD;
&#xD;
          4. For phakic patients, able and willing to avoid supine position until gas resolution&#xD;
             (approximately 6 to 8 weeks).&#xD;
&#xD;
          5. Able and willing to wear wristband that informs any medical personnel that the patient&#xD;
             has a gas bubble in the eye&#xD;
&#xD;
             Exclusion&#xD;
&#xD;
             A potential participant is not eligible if any of the following exclusion criteria are&#xD;
             present:&#xD;
&#xD;
          6. A condition that, in the opinion of the investigator, would preclude participation in&#xD;
             the study (e.g., unstable medical status that might preclude completion of follow-up)&#xD;
&#xD;
          7. Participation in an investigational trial within 30 days of randomization that&#xD;
             involves treatment with any drug or device that has not received regulatory approval&#xD;
             for the indication being studied at the time of study entry&#xD;
&#xD;
             • Note: study participants should not receive another investigational drug/device&#xD;
             while participating in the study&#xD;
&#xD;
          8. Known contraindication to any component of the treatment&#xD;
&#xD;
          9. Known allergy to any drug used in the procedure prep (including povidone iodine)&#xD;
&#xD;
         10. Potential participant is expecting to move out of the area of the clinical center to&#xD;
             an area not covered by another clinical center during the next 6 months following&#xD;
             randomization&#xD;
&#xD;
         11. Anticipated surgery requiring anesthesia within the next 6 months following&#xD;
             randomization&#xD;
&#xD;
             • Participants cannot receive nitrous oxide until gas resolution&#xD;
&#xD;
         12. For women of child-bearing potential, pregnant at the time of enrollment&#xD;
&#xD;
             • Women who are potential study participants should be questioned about the potential&#xD;
             for pregnancy. Investigator judgement may be used to determine when a pregnancy test&#xD;
             is needed.&#xD;
&#xD;
             Study Eye Criteria&#xD;
&#xD;
             The participant must have at least one eye meeting all of the inclusion criteria and&#xD;
             none of the exclusion criteria listed below.&#xD;
&#xD;
             A participant can have only one study eye. If both eyes are eligible at the time of&#xD;
             randomization, the study eye will be selected by the investigator and participant&#xD;
             before randomization.&#xD;
&#xD;
             The eligibility criteria for a study eye are as follows:&#xD;
&#xD;
             Inclusion&#xD;
&#xD;
               1. Vitreomacular adhesion on OCT that is no larger than 3000 microns with visible&#xD;
                  separation of the vitreous on either side as seen on horizontal and vertical&#xD;
                  scans, confirmed by central reading center Note: presence of epiretinal membrane&#xD;
                  is neither a requirement nor exclusion.&#xD;
&#xD;
               2. Decreased visual function (e.g. metamorphopsia or other visual symptom) that is&#xD;
                  attributed to VMT.&#xD;
&#xD;
             Examples of visual symptoms include:&#xD;
&#xD;
             a) Distortion and/or reduction in visual acuity b) Recognized difficulty with reading,&#xD;
             driving, or using a computer c) Patient recognized interference with quality of life&#xD;
             because of a and/or b.&#xD;
&#xD;
             c. Visual acuity letter score of at least 19 (approximate Snellen equivalent 20/400 or&#xD;
             better) and at most 78 (20/32 or worse) d. Investigator and participant willing to&#xD;
             wait 6 months before surgical intervention, provided visual acuity remains stable&#xD;
&#xD;
             • An eye that requires prompt treatment for VMT should not be enrolled&#xD;
&#xD;
             Exclusion e. Other ocular condition that might affect visual acuity during the course&#xD;
             of the study or require intraocular treatment (e.g., retinal vein occlusion,&#xD;
             substantial age-related macular degeneration, or macular edema induced by a condition&#xD;
             other than VMT) • If diabetic retinopathy is present, severity level must be&#xD;
             microaneurysms only or better (≤ diabetic retinopathy severity level 20)&#xD;
&#xD;
             • Presence of drusen is acceptable; however, eyes with geographic atrophy or&#xD;
             neovascular age-related macular degeneration involving the macula are excluded f. High&#xD;
             level of myopia (spherical equivalent of -8.00 diopters or more myopic if phakic or&#xD;
             retinal abnormalities consistent with pathologic myopia if phakic or pseudophakic) g.&#xD;
             History of prior gas injection, ocriplasmin injection, or intraocular injection for&#xD;
             any reason h. History of prior vitrectomy i. History of uncontrolled glaucoma&#xD;
&#xD;
             • IOP must be &lt;30 mmHg, with no more than one topical glaucoma medication, and no&#xD;
             documented glaucomatous field loss for the eye to be eligible j. History of major&#xD;
             ocular surgery (including cataract extraction, scleral buckle, any intraocular&#xD;
             surgery, etc.) within prior 4 months or major ocular surgery anticipated within the&#xD;
             next 6 months following randomization k. History of YAG capsulotomy performed within 4&#xD;
             months prior to randomization l. Aphakia or anterior chamber intraocular lens m. Exam&#xD;
             evidence of severe external ocular infection, including conjunctivitis, chalazion, or&#xD;
             substantial blepharitis n. Uveitis o. Presence of any macular hole or lamellar hole&#xD;
             (according to reading center grading) p. Retinal history or pathology that might&#xD;
             predispose an eye to an increased risk of retinal detachment from the procedure&#xD;
&#xD;
             • Untreated retinal tears, not retinal holes, are an exclusion. It is up to the&#xD;
             investigator to determine whether extent of lattice degeneration or other pathology&#xD;
             might increase the risk of retinal detachment.&#xD;
&#xD;
             q. Any contraindication to paracentesis (e.g., history of narrow angle glaucoma) r.&#xD;
             Lenticular or zonular instability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clement Chan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Southern California Desert Retina Consultants, MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Diagnostic Center</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantis Eye Care</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647-8693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040-4123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Retina Consultants, Inc</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-3028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants, MC</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Med., Dept of Ophthalmology, Jacksonville Hlth Sci Ctr</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-1101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Eye Institute, PA dba Eye Associates of Pinellas</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782-4418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center, PC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Eye Group</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gailey Eye Clinic</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704-2484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates, S.C.</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, M.D., P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266-7705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Retina Consultants, P.A.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001-7502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Northeast Louisiana dba Haik Humble Eye Center</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291-4452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, PA</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Eye Physicians and Surgeons</name>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <zip>01432-1191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates, PC</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Department of Opthalmology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128-1729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MaculaCare</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Clinical Research, LLC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose, and Throat Assoc., PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013-9791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Retina, LLP</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401-7701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-1169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <results_first_submitted>August 25, 2021</results_first_submitted>
  <results_first_submitted_qc>October 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03647267/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03647267/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pneumatic Vitreolysis (PVL)</title>
          <description>Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>For sham injections, the hub of a needleless syringe was pressed against the conjunctival surface to simulate the pressure of an injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pneumatic Vitreolysis (PVL)</title>
          <description>Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>For sham injections, the hub of a needleless syringe was pressed against the conjunctival surface to simulate the pressure of an injection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="10"/>
                    <measurement group_id="B2" value="75" spread="8"/>
                    <measurement group_id="B3" value="72" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-Hispanic Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>E-ETDRS visual acuity letter score</title>
          <description>Measure Description: Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="10.3"/>
                    <measurement group_id="B2" value="69.2" spread="8.4"/>
                    <measurement group_id="B3" value="68.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="4"/>
                    <measurement group_id="B2" value="14" spread="3"/>
                    <measurement group_id="B3" value="15" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens status on clinical exam</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Phakic (natural lens)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Chamber intraocular lens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epiretinal membrane in central subfield</title>
          <description>Randomization stratification factor</description>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Width of vitreomacular attachment that extends within the central subfield</title>
          <units>Microns</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="480" lower_limit="315" upper_limit="694"/>
                    <measurement group_id="B2" value="503" lower_limit="427" upper_limit="646"/>
                    <measurement group_id="B3" value="495" lower_limit="342" upper_limit="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loss of ellipsoid zone integrity in central subfield</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loss of ellipsoid zone integrity in foveal center</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy</title>
        <time_frame>at 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis (PVL)</title>
            <description>Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>For sham injections, the hub of a needleless syringe was pressed against the conjunctival surface to simulate the pressure of an injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy</title>
          <units>percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Rescue Treatment Before the 24-week Visit</title>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis (PVL)</title>
            <description>Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>For sham injections, the hub of a needleless syringe was pressed against the conjunctival surface to simulate the pressure of an injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Rescue Treatment Before the 24-week Visit</title>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Rescue Vitrectomy Completed Before the 24-week Visit or Planned at the 24 Week Visit</title>
        <description>scheduled rescue vitrectomy must be completed within the subsequent 12 weeks.</description>
        <time_frame>through 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis</title>
            <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.&#xD;
Pneumatic Vitreolysis (C3F8 injection): Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Participants randomized to the observation group will receive a sham injection.&#xD;
Observation: No intervention; sham injection only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Rescue Vitrectomy Completed Before the 24-week Visit or Planned at the 24 Week Visit</title>
          <description>scheduled rescue vitrectomy must be completed within the subsequent 12 weeks.</description>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Central Vitreomacular Traction Status</title>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis</title>
            <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.&#xD;
Pneumatic Vitreolysis (C3F8 injection): Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Participants randomized to the observation group will receive a sham injection.&#xD;
Observation: No intervention; sham injection only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Central Vitreomacular Traction Status</title>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Released without rescue vitrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Released with rescue vitrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not released and no rescue vitrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not released despite rescue vitrectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis</title>
            <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.&#xD;
Pneumatic Vitreolysis (C3F8 injection): Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Participants randomized to the observation group will receive a sham injection.&#xD;
Observation: No intervention; sham injection only</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="12.4"/>
                    <measurement group_id="O2" value="6.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pneumatic Vitreolysis</title>
            <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.&#xD;
Pneumatic Vitreolysis (C3F8 injection): Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Participants randomized to the observation group will receive a sham injection.&#xD;
Observation: No intervention; sham injection only</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent &lt;20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="12.4"/>
                    <measurement group_id="O2" value="6.1" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24- weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pneumatic Vitreolysis</title>
          <description>Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.&#xD;
Pneumatic Vitreolysis (C3F8 injection): Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.</description>
        </group>
        <group group_id="E2">
          <title>Observation</title>
          <description>Participants randomized to the observation group will receive a sham injection.&#xD;
Observation: No intervention; sham injection only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract traumatic (ocular injury)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.01</frequency_threshold>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anterior chamber flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Corneal edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Epiretinal membrane</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nuclear sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Posterior vitreous detachment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Stye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Subconjunctival hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Visual disturbances</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Visual flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vitreous debris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Glassman</name_or_title>
      <organization>JAEB CENTER FOR HEALTH RESEARCH</organization>
      <phone>8139758690</phone>
      <email>drcrnet@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

